JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Allogene Therapeutics Inc

Open

SectorHealthcare

1.24 2.48

Overview

Share price change

24h

Current

Min

1.22

Max

1.3

Key metrics

By Trading Economics

Income

8.8M

-51M

Profit margin

272,450

Employees

226

EBITDA

-335K

-57M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+664.23% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

61M

286M

Previous open

-1.24

Previous close

1.24

News Sentiment

By Acuity

44%

56%

140 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Oct 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 Oct 2025, 23:25 UTC

Earnings

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 Oct 2025, 23:18 UTC

Earnings

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 Oct 2025, 22:20 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 Oct 2025, 22:13 UTC

Earnings

Wal-Mart de Mexico Net Profit Falls in 3Q

28 Oct 2025, 21:38 UTC

Earnings

Correction to Visa Sales Jump Article

28 Oct 2025, 21:17 UTC

Earnings

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 Oct 2025, 21:07 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- Update

28 Oct 2025, 21:02 UTC

Earnings

Mondelez Tempers Outlook as Costs Rise

28 Oct 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 Oct 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 Oct 2025, 23:02 UTC

Earnings

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 Oct 2025, 23:01 UTC

Earnings

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 Oct 2025, 22:46 UTC

Earnings

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 Oct 2025, 22:45 UTC

Earnings

SK Hynix 3Q Net KRW12.6T >000660.SE

28 Oct 2025, 22:44 UTC

Earnings

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 Oct 2025, 22:43 UTC

Earnings

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 Oct 2025, 22:42 UTC

Earnings

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 Oct 2025, 22:20 UTC

Earnings

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 Oct 2025, 22:02 UTC

Earnings

Review & Preview: Earnings Extravaganza -- Barrons.com

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 Oct 2025, 21:20 UTC

Earnings

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 Oct 2025, 21:19 UTC

Earnings

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 Oct 2025, 21:18 UTC

Earnings

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

664.23% upside

12 Months Forecast

Average 9.4 USD  664.23%

High 14 USD

Low 7 USD

Based on 10 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

7

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

1.18 / 1.69Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

140 / 373 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat